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Skeletal muscle size is physiologically regulated by load and activity, and can decrease when 25 load is reduced. Muscle also atrophies, or decreases in size, in pathological conditions such as 26 cancer, immobilization and denervation (1). One setting where muscle mass and function are 27 diminished is old age. This loss of muscle is called sarcopenia, and it is associated with a 28 decrease in the ability to move, leading to morbidity and ultimately mortality (2); indeed, a 29 decrease in walking speed is one of the strongest predictors of mortality in humans, and this 30 finding is associated with sarcopenia (3, 4). In addition to frailty and sarcopenia, aging of course 31 affects every tissue system and greatly increases susceptibility to other serious diseases and co-32 morbidities, such as cancer, heart failure, chronic kidney disease, loss of vision, dementia and
33
Alzheimer's disease (1, 5, 6).
34
Experimental data strongly suggest the coordinated regulation of aging by distinct 35 molecular pathways (7); modulation of these pathways can counteract several age-related 36 diseases and co-morbidities, and prolong life (7-10). Of these signaling pathways, genetic or 37 pharmacological inhibition of the mammalian target of rapamycin (mTORC1) is thus far the and is sensitive to inhibition by rapamycin and rapalogs. In addition to the anabolic function, Akt 
Results
78
Increased activation of the mTORC1 pathway with age 79 Given prior reports that mTORC1 inhibition was helpful to treat a variety of age-related 80 disorders, but also the data that mTORC1 activation is required for muscle hypertrophy, we 81 conducted a time course analysis of the mTORC1 pathway to get a full scope of how its activity 82 changes with age. In laboratory settings, Sprague Dawley rats have an average lifespan of up to 83 2.5 to 3 years (41). In our study, male rats ranging from 6-months to 27-months were used.
84
Protein lysates from gastrocnemius muscles were probed for the downstream effector of 85 mTORC1, phosphorylated ribosomal protein S6 (rpS6), as a determinant of pathway activity.
86
Basal (6 hours fasted) levels of phosphorylated rpS6 gradually increased as the rats aged, with a 87 substantial increase of about 10-fold in the oldest animals aged 27-months compared with 6-88 months. (Fig. 1A, B) . The age-related increase in mTORC1 signaling coincided with a decrease 89 in muscle mass. At 21-months gastrocnemius muscle weights declined and progressively 90 atrophied at each later time point (Fig. 1C) . Though muscle loss at this age is not a surprise, the 91 coincidence of this loss with mTORC1 activation was quite unexpected, given that it favors 92 muscle growth and hypertrophy.
93
Skeletal muscle mass and quality is improved in sarcopenic rats treated with the rapalog
94
RAD001
95
Experimental evidence shows that the use of rapalogs as therapeutic agents is beneficial in 96 extending lifespan and counteracting age-related morbidities in humans and other evolutionarily 97 diverse species (reviewed in (42)). We sought to determine whether rapalog treatment could 98 counter the pathophysiological changes associated with sarcopenia. Aging rats display signs of 99 sarcopenia beginning at 18-months (43). In the present study, aged rats (22-months) were dosed 100 daily with either vehicle or 0.15mg/kg RAD001 for 6-weeks. This dose of RAD001 is equivalent 101 to a clinical dose of 0.5mg in humans, ensuring therapeutic relevance (16). Vehicle treated young 102 adult rats (7-months) served as a comparative baseline for aging effects. At the end of the 103 treatment, aged and young adult rats were 24-months and 9-months old respectively, and will be 104 referred to as such.
105
To determine if we were able to ameliorate age-related muscle loss with rapalog 106 treatment, we measured the wet weights of the tibialis anterior (TA), plantaris, gastrocnemius, 107 and soleus muscles. Consistent with previous data, all muscles, except for the soleus muscle 108 from 24-month old vehicle treated rats had considerably reduced mass compared to 9-month old 109 rats ( Fig. 2A) . RAD001 treatment did not lead to further atrophy in any of these muscles. On the 110 contrary, rapalog appeared to be protective for aged animals, and reduced extensive muscle mass 111 loss. Plantaris and TA muscles showed a surprising increase in mass, with the TA muscle being 112 significantly increased compared to vehicle treated animals ( Fig. 2A) . Our data provide strong 113 evidence that when administered to sarcopenic rats, low dose rapalog treatment is not detrimental 114 to muscle mass. Rather, it allows for animals to maintain or gain muscle.
115
Changes in muscle mass often reflect morphological alterations in tissue. We performed 116 histological analysis on H&E stained plantaris muscle cross-sections. Tissue from 9-month old 117 rats had normal morphology, typical of healthy muscle (Fig. 2B) . In contrast, we detected several 118 indicators of distressed muscle in aged animals that received only vehicle. A high proportion of 119 fibers had a smaller cross-sectional area, a phenotype associated with muscle atrophy (Fig. 2D , 120 E). Moreover, about 23% of myofibers from vehicle treated 24-month old muscles presented 121 with central nuclei, indicative of prior degeneration and ongoing regeneration (Fig. 2B, C) . There (Fig. 2E) . Taken together, these data show that a low dose rapalog treatment for 6 weeks can 128 counteract age-related morpho-pathological changes in sarcopenic skeletal muscle -especially 129 signs of degeneration requiring regeneration, as measured by the presence of central nuclei.
130
Chronic activation of the mTORC1 pathway by muscle-specific deletion of Tsc1, a 131 negative regulator of mTORC1, has been shown to cause a late-onset myopathy, with muscle 132 atrophy in young adult mice (44). Inhibition of mTORC1 activity using rapamycin was able to 133 reverse the observed pathological changes and normalize muscle mass in these animals (44).
134
Despite evidence of similarly sustained mTORC1 signaling in aged muscle, its inhibition has not Fig. 2A ), these data demonstrate that mTORC1 inhibition by RAD001 can prevent 163 further muscle loss by suppressing expression of atrophy markers.
164
The onset of senescence with age is associated with the inability to efficiently repair and 165 recover muscle, a contributing factor to the progressive decline in muscle mass in sarcopenia.
166
Cell cycle proteins Cdkn1a (p21) and Cdkn2a (p16) are known cellular senescence markers that 167 are upregulated with age in several tissues, including skeletal muscle (43, 46, 47). Relative to 9-168 month old rats, Cdkn1a (p21) and Cdkn2a (p16) are both highly expressed at the mRNA level in 169 muscle from aged vehicle treated rats (Fig. 4B) . RAD001 significantly reduced Cdkn1a and 170 Cdkn2a mRNA levels in 24-month old muscles compared to age-matched vehicle treated 171 controls (Fig. 4B) . Gadd45a, known to be markers of functional denervation (43), were determined by RT-qPCR. In 180 agreement with our previous observations, all of these genes were significantly upregulated in 181 muscles from vehicle treated 24-month old animals compared to 9-month old controls (Fig. 5) .
182
Interestingly, treatment of aged animals with RAD001 reduced the transcriptional upregulation 183 of these denervation-associated gene markers in relation to their vehicle treated age-matched 184 counterparts (Fig. 5) . These data suggest that suppressing the mTORC1 pathway in aged animals 185 could be protective against age-associated denervation. Age-associated diseases comprise many of the most serious conditions afflicting human beings: 189 sarcopenia and frailty, cancer, heart disease, Alzheimer's disease, and chronic kidney disease.
190
The mTORC1 inhibitor rapamycin and its analogs (rapalogs) have been shown to extend lifespan
191
(12-15) and delay many of these age-related conditions (9-11). These findings have even been We were surprised to see that skeletal muscle mass increased rather than decreased as a 209 result of mTORC1 inhibition. This was not due to adverse events such as edema; muscles - MT1 was downregulated by mTORC1 inhibition. We had previously shown that this is a high-226 fidelity marker of atrophy, and knocking out the MT genes in mice causes muscle hypertrophy 227 (45). This finding too is consistent with the increase in mass observed in the present study, and 228 provides further mechanistic rationale. As for the senescence markers p16 and p21, they were 229 elevated in aged muscle when compared to young muscle, and reversed towards the "younger Anti-rabbit and anti-mouse IgG HRP-conjugated secondary antibodies were also from Cell
282
Signaling Technologies. Densitometric analysis was performed using Fiji 1.51n software. used to determine morphological changes, including the incidence of central nuclei. group, except where specified. All data are displayed as means with standard deviation.
332
GraphPad Prism 7.04 software was used for calculations and graphing.
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